A panel of isogenic cell-lines covering a wide range of human disease genotypes enables drug discovery researchers to determine the optimal patient populations to target with their drug candidates in the expensive clinical trial stage of the drug development process.

Here we show proof-of-concept that in vitro isogenic cell-lines do indeed predict responses in humans carrying the same cancer gene.

The availability of such data enables researchers to determine the full range of sensitive and resistant patient populations to the disease target in clinical trials. This will enable the design of smaller more efficient clinical trials that read-out quicker and be more likely to succeed and reduce the high-rate of attrition currently observed at this critical phase of drug development.

Horizon Offering

Horizon Discovery has a wide range of isogenic models available for immediate licensing or purchasing (learn more) and; can also develop custom isogenic models (learn more) or screen drug candidates against your specific gene target (learn more).

Additional data-sets are available for each application and can be shared under confidential disclosure agreement. Please contact us for more information.

References

• Featured publications
• All publications

Downloads

• Horizon Technology Presentation